Accuray (ARAY) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
16 Jan, 2026Executive summary
Q1 FY2025 net revenue was $101.5 million, down 2% year-over-year, with strong China growth, robust service revenue, and a successful Tomo C product launch.
Service revenue grew 5% year-over-year, outpacing installed base growth and reflecting enhanced contract offerings.
Adjusted EBITDA for Q1 was $3.1 million, down from $6.5 million in the prior year, mainly due to one-time ERP-related benefits last year.
Net loss widened to $4.0 million ($0.04/share) from $3.0 million ($0.03/share) year-over-year.
Raised full-year FY2025 guidance for both revenue and Adjusted EBITDA, reflecting confidence in backlog and market trends.
Financial highlights
Q1 FY2025 revenue was $101.5 million, down 2% year-over-year; product revenue was $48.4 million (down 9%), service revenue was $53.2 million (up 5%).
Gross margin was 33.9%, down from 38.0% year-over-year, impacted by deferred gross profit on JV sales and higher costs.
Operating expenses were $36.6 million, slightly down from $37.3 million year-over-year.
Book-to-bill ratio for Q1 was 1.1; trailing 12-month ratio was 1.5.
Order backlog at quarter-end was $468.6 million, down 4% year-over-year.
Outlook and guidance
FY2025 revenue guidance raised to $462 million–$472 million; Adjusted EBITDA guidance increased to $28 million–$30 million.
U.S. market recovery expected in the second half of FY2025, with delayed system revenue and margin realization.
Second half of FY2025 expected to contribute 55% of total revenue, with Q4 as the largest quarter.
Projected GAAP net loss for FY2025 is $2.5 million–$4.5 million.
Guidance includes $3 million–$4 million of net margin release from China JV.
Latest events from Accuray
- Shelf registration covers resale of 7M shares from warrants tied to recent financing.ARAY
Registration Filing17 Feb 2026 - Revenue and margin guidance cut as China headwinds, tariffs, and financing changes weigh.ARAY
Q2 202617 Feb 2026 - Record Q4 revenue and robust FY25 outlook highlight strong growth and global expansion.ARAY
Q4 20241 Feb 2026 - Growth driven by innovation, emerging markets, and margin expansion, with U.S. recovery expected.ARAY
Jefferies Global Healthcare Conference31 Jan 2026 - Q3 FY25 revenue up 12%, net loss narrowed, but guidance cut on tariffs; EBITDA improved.ARAY
Q3 202527 Dec 2025 - Q2 revenue up 8% to $116.2M, net income $2.5M, margin 36.1%, guidance raised.ARAY
Q2 202524 Dec 2025 - Resale registration covers 23.4M shares from warrant exercises tied to recent financing.ARAY
Registration Filing16 Dec 2025 - Shareholders will vote on director elections, equity plan increases, pay, and auditor ratification.ARAY
Proxy Filing1 Dec 2025 - Major leadership changes and transformation plan target growth, margin expansion, and agility.ARAY
Proxy Filing1 Dec 2025